Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Regenerative Medical Technology Group EV-to-EBITDA?
Regenerative Medical Technology GroupRMTG +17.25% EV-to-EBITDA is 17.90 as of Aug. 21, 2026. The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 55.47% on this metric.
RMTG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -228.75 Med: -1.24 Max: 65.2
Current: 17.9
During the past 9 years, the highest EV-to-EBITDA of Regenerative Medical Technology Group was 65.20. The lowest was -228.75. And the median was -1.24.
RMTG's EV-to-EBITDA is ranked worse than 55.47% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs RMTG: 17.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Regenerative Medical Technology Group (OTCPK:RMTG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regenerative Medical Technology Group's PE Ratio (TTM) for today is calculated as:
Regenerative Medical Technology Group's share price for today is $0.07.
Regenerative Medical Technology Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group EV-to-EBITDA Chart
RMTG vs ABPO, CLSDQ, SCNI: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group EV-to-EBITDA vs Biotechnology Industry
Regenerative Medical Technology Group's current Enterprise Value is $20.44 Mil.
Regenerative Medical Technology Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a EV-to-EBITDA of 17.90 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regenerative Medical Technology Group. According to the industry distribution chart, Regenerative Medical Technology Group ranks #223 out of 402 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Regenerative Medical Technology Group's EV-to-EBITDA too high?
Regenerative Medical Technology Group's current EV-to-EBITDA is 17.90. The Biotechnology industry median EV-to-EBITDA is 14.41. Regenerative Medical Technology Group's value of 17.90 is 24.2% above this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #223 out of 402 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regenerative Medical Technology Group's EV-to-EBITDA compare to ABPO and CLSDQ?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #223 out of 402 companies for EV-to-EBITDA. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.41. Regenerative Medical Technology Group's value of 17.90 is 24.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current EV-to-EBITDA of 17.90 is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regenerative Medical Technology Group. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current EV-to-EBITDA is 17.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.07 — trading 16.7% above its estimated fair value. The current EV-to-EBITDA is 17.90 and 24.2% above the Biotechnology industry median of 14.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current EV-to-EBITDA is 17.90 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 
